Compare · CDIO vs NEOG
CDIO vs NEOG
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $1.97B, about 335.2x CDIO ($5.9M).
- NEOG has been more active in the news (3 items in the past 4 weeks vs 2 for CDIO).
- NEOG has more recent analyst coverage (5 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- Neogen Corporation
- Price
- $1.96-0.51%
- $9.07+1.85%
- Market cap
- $5.9M
- $1.97B
- 1M return
- +7.69%
- -
- 1Y return
- -58.91%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1989
- News (4w)
- 2
- 3
- Recent ratings
- 0
- 5
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest CDIO
- Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
- IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Fung Peter K
- SEC Form 4 filed by Betts Wendy J
- SEC Form 4 filed by Intrater James
- SEC Form 4 filed by Burton Paul Frederick
- SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest NEOG
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,553 units of Restricted Stock Units, decreasing direct ownership by 10% to 23,571 units (SEC Form 4)
- SEC Form SD filed by Neogen Corporation
- Former Chief Legal Officer Rocklin Amy M exercised 35,183 shares at a strike of $9.29 and covered exercise/tax liability with 10,241 shares, increasing direct ownership by 44% to 82,182 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $9.53 and covered exercise/tax liability with 1,568 shares, increasing direct ownership by 21% to 17,337 units (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares (SEC Form 4)
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits